Opthea Ltd

$0.015

$0.001 (3.33%)

Day Range

$0.014 – $0.015

52 Week Range

$0.012 – $0.025

Volume

4.70M

Avg Volume (10D)

136.56M

Market Cap

$19.84M

Price Chart

Market Statistics

Open$0.015

Previous Close$0.015

Day High$0.015

Day Low$0.014

52 Week High$0.025

52 Week Low$0.012

Valuation

Market Cap19.84M

Shares Outstanding1.37B

P/E Ratio (TTM)0.07

Price to Book0.65

Trading Activity

Volume4.70M

Value Traded69.11K

Bid$0.014 × 13,902,195

Ask$0.015 × 3,124,437

Performance

1 Day6.67%

5 Day23.08%

Opthea achieves positive vision trial, eyes further clinical trials

Biopharmaceutical company Opthea (ASX: OPT) has taken an affirmative step towards commercialising its OPT-302 combination therapy after publishing positive phase 2b clinical trial results that included 366 patients. With the results published the biopharma company claims that PT-302 may emerge as a combination treatment that can offer better vision gains than currently available care with […]

By George Tchetvertakov··3 min read min read

Biotechnology

Opthea starts trial for OPT-302 drug in diabetic eye diseases

Biopharmaceutical company Opthea (ASX: OPT) has started a Phase 1b/2a trial investigating the effectiveness of its OPT-302 drug in diabetic eye diseases. Diabetic macular edema leads to the thickening of the retina caused by leaky blood vessels. The disease is the leading cause of blindness in diabetes and affects more than two million people around […]

By Lorna Nicholas··1 min read min read